It has been discovered by a team of pharmacists from Gilead Sciences Inc. (GILD) recent Friday that the hepatitis C patients have shown a relapse in their disease after a trial of an experimental drug was stopped. The drug is now being questioned by many for showing such after consequences, says the report.

According to the report findings, the company has been facing the maximum share price drop in past 11 years due to the results shown by the drug GS-7977, plus ribavirin. It has been found that the company had purchased the hepatitis C therapies of Pharmasset at $10.8 billion the previous year. However, the drug’s potential has been in question in these days.

Hepatitis C genotype 1 has been reported to be the most common disease in the US, which has been targeting a lot many people throughout the nation. It was found by the firm’s team of researchers that six patients amongst a total of eight had been diagnosed with a relapse of the disease and that also within four weeks after stopping the 12-week drug trial. While the ones whose medicine has been stopped just two weeks ago, have not shown any such results.

It is being said that the recurrence of hepatitis C genotype 1 in patients after the halt of therapy trial has made Gilead Sciences, the company based in Foster City, to experience a fall 14% to $47 in the past 11 years i. e. since the month of January 2001. In addition, the reporters have also been told that the huge decline in company’s shares has narrowed its profit for the last one year and has brought it to 20%.

Whereas the company’s rivals have grown up, reveals the report. It has been found that Vertex has joined Merck & Co. so as to get approval for new hepatitis C drugs as well as Idenix has developed a drug against the same.